ArticlesEffects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study
Introduction
Acute renal failure (ARF) is a common complication of severe sepsis and septic shock.1, 2, 3 Correction of volume depletion is crucial to the prevention of acute tubular necrosis, which is associated with mortality of about 75% in septic shock.4 The optimum fluid restoration regimen has not been defined, and clinical practice varies.5, 6 Hydroxyethylstarches are among the most widely used compounds because their volume-expanding effect is both large and long-lasting.5 However, the use of these substances in a selected population of brain-dead kidney donors was associated with immediate impairment of renal function in the transplant recipients.7 A combination of extreme renal ischaemia and osmotic-nephrosis-like lesions seemed a plausible explanation for this finding.8 However, the potential for hydroxyethylstarches to impair rena function remains controversial.9
Patients with severe sepsis or septic shock are at risk of ischaemic renal injury, and they require large amounts of plasma-volume expanders.1, 3 Prevention of renal dysfunction in patients with sepsis is crucial, because there is no curative treatment for acute tubular necrosis. To explore the possibility that the type of expander used may influence the renal outcome, we undertook a multicentre prospective randomised study in patients with severe sepsis or septic shock in intensive-care units. Our prospectively defined hypothesis was that the frequency of ARF would be lower when gelatin rather than hydroxyethylstarch was used as the plasma-volume expander. Our clinical objective was to assist in the choice of the optimum plasma-volume expander in patients at risk of renal impairment. No subgroup or covariate analyses were planned.
Section snippets
Patients
The study took place between April, 1998, and September, 1999, in the intensive-care units of three French hospitals, two medical units in university hospitals and one medical-surgical unit in a public community hospital. The institutional review board of these hospitals approved the study protocol. Before enrolment, informed consent was obtained from the patient, if possible, or from the patient's next of kin or legal representative.
Patients aged 18 years or older were eligible if they had
Results
Of 328 patients screened, 129 were eligible and consented to take part in the study (figure 1). The study groups were similar at admission to the intensive-care unit and at study inclusion (table 1). 26 patients in the hydroxyethylstarch group and 20 in the gelatin group were enrolled more than 24 h after admission to the intensive-care unit. The main sites of infection were the lungs (44% in the hydroxyethylstarch group, 52% in the gelatin group), the abdomen (9%, 5%), and the urinary tract
Discussion
None of the currently available plasma expanders offers a clear clinical advantage over the others. Whether crystalloids or colloids are preferable and whether one colloid is better than the others have been debated for three decades. No conclusive data on outcomes and adverse events are available to settle the issue.6, 9, 17, 18 Hydroxyethylstarch, a colloid plasma substitute, has been available for more than 20 years. It is a polymer of amylopectin substituted with hydroxyethyl groups to
References (33)
- et al.
Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients
Lancet
(1996) - et al.
Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation
Lancet
(1993) - et al.
Accumulation of hydroxyethyl starches (HES) in the liver of patients with renal failure and portal hypertension
J Hepatol
(1986) - et al.
Tissue deposits of hydroxyethyl starches (HES): dose-dependent and timerelated
Br J Anaesth
(1999) - et al.
Incidence, risk factors, and outcome of severe sepsis and septic shock in adults: a multicentre prospective study in intensive care units
JAMA
(1995) - et al.
The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study
JAMA
(1995) - et al.
Pathogenesis of renal failure in sepsis
Kidney Int Suppl
(1998) - et al.
Prognostic factors in acute renal failure due to sepsis: results of a prospective multicentre study
Nephrol Dial Transplant
(1996) - et al.
Volume replacement strategies in intensive care units: results from a postal survey
Intensive Care Med
(1998) - et al.
Crystalloids vs colloids in fluid resuscitation: a systematic review
Crit Care Med
(1999)
An international view of hydroxyethyl starches
Intensive Care Med
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
Crit Care Med
Utilisation des catecholamines au cours du choc septique
Réanimation Urgence
Practice parameters for hemodynamic support of sepsis in adult patients in sepsis
Crit Care Med
Gram negative bacteremia, etiology and ecology
Arch Intern Med
A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study
Jama
Cited by (625)
Perioperative Fluid Management
2023, Anesthesiology ClinicsAcute Kidney Injury and Renal Replacement Therapy: A Review and Update for the Perioperative Physician
2023, Anesthesiology ClinicsPerioperative Management of the Patient at High-Risk for Cardiac Surgery-Associated Acute Kidney Injury
2022, Journal of Cardiothoracic and Vascular AnesthesiaPreservation of Renal Function
2021, Perioperative Medicine: Managing for Outcome, Second Editionlntraoperative administration of 6% hydroxyethyl starch 130/0.4 is not associated with acute kidney injury in elective non-cardiac surgery: A sequential and propensity-matched analysis
2020, Anaesthesia Critical Care and Pain MedicineIntraoperative Colloid Use on Post-operative Renal Function
2024, Current Anesthesiology Reports